semaglutide pancreatitis GLP-1s May Lower Risk of Acute in Patients with T2D, Obesity New Weight-Loss Drugs Under Scrutiny

Titration pacing matters In the Phase 2 NEJM trial, GI side effect rates nearly doubled when participants jumped to 8 mg instead of climbing gradually from 1-2 mg

Higher Possibility of Dosing Errors Compounded versions of semaglutide can differ significantly from the approved versions in terms of packaging (like multi-dose vials or pre-filled syringes), concentrations, and dosing instructions

Nutritional strategies for treating chronic fatigue syndrome

Founder of PHARMeMED | 2M+ Pharma & Life Sciences Network | Drug Development & Biotech Industry Analyst | Drug Development, Biotech, R&D, Medical Affairs & Clinical Research Lillys Next Big Move in Obesity & Diabetes: A Pill That Rivals Injectables Eli Lilly just dropped major Phase 3 results and they could reshape the weight-loss and diabetes market once again